Lixte Biotechnology Holdings (LIXT) Peer Comparison

$3.66

$-0.65 (-15.08%)

As on 03-Sep-2026 09:30EDT

Market cap

$125 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.3

Div. Yield

0 %

Edit

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	125	16,765	16,261	13,492	12,332
Revenue ($ Mln)	--	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-8.69	491.50	755.85	860.62	-325.10
Net Margin (%)	--	17.67	71.69	35.33	-25.32
RoE (%)	-51.36	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	3.33	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	0.00	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	0.00	1,982.07	103.47	85.67	109.42
Gross Profit	--	760.62	588.53	2,236.43	902.26
Operating Expenses	7.96	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-7.96	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-8.75	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-8.69	491.50	755.85	860.62	-325.10
Minority Interest	0.06	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	23.91	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.06	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.16	187.89	384.48	288.55	346.72
Current Liabilities	1.50	1,435.43	464.70	361.93	374.20
Total Liabilities	12.73	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	7.35	1,006.90	895.24	1,243.41	45.47
Current Assets	19.30	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	12.73	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	1.10	120.10	449.89	165.93	347.75
Net Current Assets	0.00	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-3.07	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-3.17	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	10.31	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-107.74	53.56	-30.01	32.82	-31.49
ROE (%)	-51.36	110.09	163.18	42.98	-57.72
ROA (%)	-36.44	15.64	26.53	29.32	-22.97
EBIT Margin (%)	--	21.13	5.73	31.04	-18.97
Net Margin (%)	--	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	--	24.67	114.85	9.23	149.04
EBIT Growth (%)	-221,534.63	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	-181.18	17.50	378.76	42.89	-15.32
EPS Growth (%)	43.93	26.84	353.27	50.42	-0.64
Book Value Growth (%)	641.02	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-31.66	36.06	-59.76	15.79	-45.32
Price / Book Value	19.69	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-30.96	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.04	0.00	0.05	0.00	0.00
Current Ratio	12.87	0.73	2.99	3.46	3.20
Quick Ratio	12.87	0.73	2.32	3.38	2.94
Interest Coverage	-1,353.84	--	1.62	--	-19.80

Operating Efficiency Ratios

	Lixte Biotechnology Holdings (LIXT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	--	15.88	21.25	13.74	14.98
Asset Turnover	0.00	0.89	0.37	0.83	0.91
Receivable days	--	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	--	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly